Premium
Recovery of baseline lung function after pulmonary exacerbation in children with primary ciliary dyskinesia
Author(s) -
Sunther Meera,
Bush Andrew,
Hogg Claire,
McCann Lauren,
Carr Siobhán B.
Publication year - 2016
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.23479
Subject(s) - medicine , primary ciliary dyskinesia , exacerbation , spirometry , pulmonary function testing , clinical endpoint , vital capacity , cystic fibrosis , lung , anesthesia , clinical trial , asthma , lung function , bronchiectasis , diffusing capacity
Summary Rationale Spirometry in children with cystic fibrosis (CF) frequently fails to return to baseline after treatment for a pulmonary exacerbation. It is unclear whether the same is true for children with primary ciliary dyskinesia (PCD). Objectives To determine in children with PCD treated with intravenous antibiotics for a pulmonary exacerbation: (1) the proportion who recover to baseline forced expiratory volume at 1 sec (FEV 1 ) within 3 months after treatment and (2) to try to identify factors which are associated with failure to regain pre‐exacerbation FEV 1 . Methods Cohort study using the PCD database for children at the Royal Brompton Hospital, 2003–2013. We selected the first pulmonary exacerbation treated with intravenous antibiotics. The best FEV 1 within 3 months after treatment was compared to the best FEV 1 in the 12 months before treatment (baseline). Recovery to baseline was defined as any FEV 1 after treatment that was greater than or equal to 90% of the baseline FEV 1 . Results 32/150 children (21%) had at least one pulmonary exacerbation. 23/30 (77%) regained baseline spirometry within 3 months of treatment. There was no difference between responders and non‐responders in any baseline characteristics. Conclusions Around 25% of children with PCD fail to recover to baseline lung function within 3 months following treatment for a pulmonary exacerbation, similar to CF. Better treatment strategies are needed, and the results also suggest that prevention of exacerbations would be a useful end‐point in clinical trials. Pediatr Pulmonol. 2016;51:1362–1366. © 2016 Wiley Periodicals, Inc.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom